A phase III clinical trial for treatment of osteolytic lesions in MM patients, showed the efficacy and safety of RANKL inhibitor denosumab, which mimics the endogenous OPG effects [205]. This evidence concerns the gene TNFSF11 and Miyoshi myopathy.